$695 – $3,980

Event Information

Share this event

Date and Time



Radisson Blu Hotel, Berlin

Karl-Liebknecht-Straße 3

10178 Berlin


View Map

Refund Policy

Refund Policy

No Refunds

Friends Who Are Going
Event description


We invite you to attend the European Pharma Summit 2017 in Berlin, Germany on November 16-17, 2017. This event seeks to create a forum for colleagues across multiple disciplines, from both private and public sectors, to gather and exchange ideas. Delegates from pharmaceutical organizations, biotech companies, and leading academic institutions will gather to listen to presentations on innovative findings in drug discovery and network with both new and old colleagues.

The landscape for drug design has changed drastically over the past few years: private and public partnerships are changing how research is being done, researchers are using 3D model systems in hopes of improving clinical outcomes, and emerging target classes are changing traditional concepts of the drug discovery process.

The European Pharma Summit will have opening and closing plenary sessions on the following:

  1. Chemical Biology for Target Identification and Validation
  2. Hot Topics in Drug Discovery for the Future

12th Drug Design & Medicinal Chemistry

  1. Tools and Technologies for Drug Discovery
  2. Novel Computational Methods & Predictive Models
  3. Targeting the Regulatory Proteome
  4. Epigenetic Based Inhibitors

5th GPCR Targeted Screening

  1. GPCR Structure-Based Drug Discovery
  2. GPCR Signaling Pathways and Mechanisms
  3. GPCRs in Metabolism
  4. Screening Technologies for GPCRs

3rd Kinase Inhibitors in Drug Discovery

  1. Technological Advances for Studying the Kinome
  2. Novel & Alternative Approaches in Drug Discovery
  3. Optimizing Target Residence Times in Kinase Drug Development
  4. Overcoming Therapeutic Resistance


Day 1 - Thursday, November 16th, 2017

Registration & Breakfast at Restaurant (included for those staying at the Radisson Blu)

Welcome & Opening Remarks

Discovery of First-in-class Reversible Inhibitors of Relevant Epigenetic Targets: DNMTs, G9a or/and HDACs
Margaret Frame

Morning Networking Break

Drug Design & Medicinal Chemistry

Tools and Technologies for Drug Discovery
Moderator: Ingo Mugge, Alkermes
Medicinal Chemistry Optimizations in Deep Water: SAR Studies on mGluR5 Allosteric Modulators

György  Keserű

György Keserű
Principal Investigator, Medicinal Chemistry
Hungarian Academy of Sciences

GPCR Targeted Screening
Screening Technologies for GPCRs

Amadeu  Llebaria

Amadeu Llebaria
Cell Biology, Molecular Biology, Cancer Research
Spanish National Research Council

Kinase Inhibitors in Drug Discovery
Technological Advances for Studying the Kinome
Computational Approaches to Study Kinase Regulation and Function

Pedro  Beltrao

Pedro Beltrao
Group Leader

High Content Analysis-Based Exploration of Steroid Receptor Functions

Michael Mancini

Michael A. Mancini
Professor, Molecular and Cellular Biology
Baylor College of Medicine

Kim  Jonas

Kim Jonas
Lecturer, Reproductive Physiology
St George's, University of London

Allosteric Inhibitor Discovery with Aurora A Kinase and Second-Harmonic Generation (SHG)

Joshua Salafsky

Joshua Salafsky
Founder and Chief Scientific Officer
Biodesy Inc.

Frank  Boeckler

Frank Boeckler
Professor, Pharmacy and Biochemistry
Eberhard Karls Universität Tübingen

TBA (To Be Announced)

Systems Biology of Oncogenic Signalling

Pedro  Cutillas

Pedro Cutillas
Reader in Cell Signalling & Protoemics, Barts Cancer Institute
Queen Mary University of London

New Directions in DNA-encoded Chemistry Through a Tailored Encoding Strategy

Andreas  Brunschweiger

Andreas Brunschweiger
Research Group Leader, Chemistry & Chemical Biology
TU Dortmund

TBA (To Be Announced)

Can CRISPR/Cas9 Discover New Synthetic Lethal Kinase Targets for Undruggable Cancer Drivers?

Jon  Moore

Jon Moore
Horizon Discovery

Lunch Provided by GTCbio for All Attendees || Lunch with Mentors for Select Participants

Drug Design & Medicinal Chemistry

Novel Computational Methods & Predictive Models

Interconversion Rates between Conformational States as Determining Factor for the Passive Membrane Permeability of Cyclic Peptides

Sereina  Riniker

Sereina Riniker
Professor, Physical Chemistry
ETH Zurich

GPCR Targeted Screening

GPCR Signaling Pathways and Mechanisms

Single-molecule Imaging of GPCR Signaling

Davide  Calebiro

Davide Calebiro
Group Leader
University of Wuerzburg

Kinase Inhibitors in Drug Discovery

Novel & Alternative Approaches in Drug Discovery

Discovery of Allosteric Inhibitors for Focal Adhesion Kinase

Daniel  Lietha

Daniel Lietha
Group Leader, Cell Signalling and Adhesion Group
Spanish National Cancer Research Centre (CNIO)

Performance of Conformal Prediction in Prospective Applications of QSAR and QSPR Models Supporting Drug Discovery

Ingo  Mugge

Ingo Mugge
Senior Research Fellow

Advanced BRET Approaches for Profiling GPCR Pharmacology

Kevin  Pfleger

Kevin Pfleger
Head, Molecular Endocrinology and Pharmacology
Harry Perkins Institute of Medical Research and The University of Western Australia

Investigating the Nature of Cryptic Pocket Formation Through Enhanced Sampling Simulations

Francesco  Gervasio

Francesco Gervasio
University College London

Gerhard  Wolber

Gerhard Wolber
Freie Universität Berlin

GPCR - G Protein Selectivity Determined by Interaction Kinetics

Moritz  Bünemann

Moritz Bünemann
Professor, Pharmacology and Clinical Pharmacy
University of Marburg

Uncoupling mTORC2 from AGC Kinases to Modulate Tumour Growth

Angus  Cameron

Angus Cameron
Principal Investigator, Tumour Biology
Barts Cancer Institute

Mike  Hann

Mike Hann
GSK Senior Fellow and Director, Drug Design and Selection

Carsten  Hoffman

Carsten Hoffman
Director, Institute of Molecular Cell Biology
University Hospital Jena

Leniolisib (CDZ173) - Discovery of a New Generation of Potent and Selective PI3Kdelta Inhibitors for the treatment of Autoimmune and Inflammatory Diseases

Nicolas Soldermann

Nicolas Soldermann
Senior Investigator and Group Leader, Global Discovery Chemistry

Afternoon Networking Break

Drug Design & Medicinal Chemistry

Targeting the Regulatory Proteome

TBA (To Be Announced)

GPCR Targeted Screening

GPCRs in Metabolism

Fluorocarbon Conjugates: New Concept to Increase the Metabolic Stability of GPCR Peptides

Dominique Bonnet

Dominique Bonnet
Scientific Officer
University of Strasbourg

Kinase Inhibitors in Drug Discovery

Optimizing Target Residence Times in Kinase Drug Development
Moderator: Henrik Moebitz, Novartis
Target Residence-guided Optimization of Kinase Inhibitors

Guido  Zaman

Guido Zaman
Managing Director & Head of Biology
Netherlands Translational Research Center

TBA (To Be Announced)

TBA (To Be Announced)

Matt  Robers

Matt Robers
Senior Research Scientist and Group Leader

TBA (To Be Announced)

TBA (To Be Announced)

Jon  Elkins

Jon Elkins
Group Head/PI, Structural Genomics Consortium
University of Oxford

Networking Reception & Poster Session

End of Day 1

Day - 2 Friday, November 17th, 2017

Breakfast at Restaurant (included for those staying at the Radisson Blu)
Drug Design & Medicinal Chemistry

Epigenetic Based Inhibitors
Moderator: Sharad Verma, Johns Hopkins University School of Medicine
The Design and Optimization of Orally Bioavailable EZH2 Inhibitors

Steven  Knight

Steven Knight
Scientific Leader, Cancer Epigenetics Discovery Performance Unit

GPCR Targeted Screening
GPCR Structure-Based Drug Discovery
Navigating Chemical Space in Search for Selective GPCR Ligands

Peter  Kolb

Peter Kolb
University of Marburg

Kinase Inhibitors in Drug Discovery
Overcoming Therapeutic Resistance
The Oncogenic Effects of PI3K Activation: Therapeutic Implications of Unexpected Functions

Igor Vivanco

Igor Vivanco
Team Leader
Institute of Cancer Research

TBA (To Be Announced)

Directed Evolution of G Protein-Coupled Receptors for Improved Expression and Stability

Christoph  Klenk

Christoph Klenk
Postdoctoral Fellow, Biochemistry
University of Zurich

Discovery of an Efficacious and Selective MEK Inhibitor with ATP-Competitive Mode of Action

Henrik  Moebitz

Henrik Moebitz
Senior Investigator, Global Discovery Chemistry

TBA (To Be Announced)

The Inner Workings of a GPCR: Signalling-Specific Conformations of Vasopressin V2 Receptor

Dmitry  Veprintsev

Dmitry Veprintsev
Professor of Molecular and Cellular Pharmacology, Centre for Membrane Proteins and Receptors
University of Nottingham

Overcoming Drug-Resistant EGFR Mutants with Allosteric Inhibitors

Michael  Eck

Michael Eck
Professor, Biological Chemistry & Molecular Pharmacology
Harvard Medical School

TBA (To Be Announced)

TBA (To Be Announced)

EGFR Triple Mutant: Recent Set-backs and New Hopes in Fighting Mutant Non-small Cell Lung Cancer

Stefan  Laufer

Stefan Laufer
Chairman Pharm. & Medicinal Chemistry, Department Pharmacy & Biochemistry
University of Tübingen

Morning Networking Break
Round Table Discussion

Lunch Provided by GTCbio for All Attendees

Conference Concludes

Please contact the event manager Marilyn below for the following:
- Discounts for registering 5 or more participants.
- If you company requires a price quotation.
Event Manager Contact: marilyn.b.turner(at)nyeventslist.com
You can also contact us if you require a visa invitation letter, after ticket purchase.
We can also provide a certificate of completion for this event if required.

This Event Listing is Promoted by
New York Media Technologies LLC in association
with GTCbio
Share with friends

Date and Time


Radisson Blu Hotel, Berlin

Karl-Liebknecht-Straße 3

10178 Berlin


View Map

Refund Policy

No Refunds

Save This Event

Event Saved